Diabetic Biomarkers Concordance Compared in South African Blacks
|
By LabMedica International staff writers Posted on 28 Jun 2021 |

Image: The D-10 Hemoglobin Testing System provides comprehensive, automated hemoglobin testing in a compact footprint, combining HbA1c and HbA2/F/A1c testing on a single platform (Photo courtesy of Bio-Rad)
Sub-Saharan Africa is projected to experience a significant increase in the prevalence of diabetes mellitus by in the near future and accurate, comparable prevalence estimates will be essential to planning and monitoring by public health authorities.
Diagnosis based on glycated hemoglobin (HbA1c) is attractive because it provides an integrated assessment of glycemic status over the preceding three months and has low analytical variability, but the extent to which this single threshold may be adopted in all sub-Saharan African populations is questionable. Existing data suggest that in individuals of African descent, HbA1c may be higher for any given degree of glycaemia than in individuals of European descent.
A large international team of medical scientists led by those at the University of the Witwatersrand (Johannesburg, South Africa) included in a study 765 black individuals aged 40–70 years and with no history of diabetes. The team investigated concordance between hemoglobin A1c (HbA1c)-defined diabetes and fasting plasma glucose (FPG)-defined diabetes in a black South African population with a high prevalence of obesity.
Capillary blood samples were tested for hemoglobin at point of collection using the Haemocue Hb 201+analyser (Haemocue, Ängelholm, Sweden). Whole blood was analyzed for HbA1c using high-performance liquid chromatography on the Bio-Rad D-10 (Bio-Rad Laboratories, Hercules, CA, USA) with a reportable range of 3.8%–18.5%. Plasma was analyzed for glucose using colorimetric methods on the Randox Plus clinical chemistry analyzer (Randox, Crumlin, UK) with a range of 0.36–35 mmol/L. Serum insulin assays were performed on the Immulite 1000 chemistry analysis system (Siemens Healthineers, Erlangen, Germany), using a solid-phase, enzyme-labeled chemiluminescent immunometric assay (range 2–300 μIU/mL).
The investigators reported that the prevalence of HbA1c-defined diabetes was four times the prevalence of FPG-defined diabetes (17.5% versus 4.2%). Classification was discordant in 15.7% of participants, with 111 individuals (14.5%) having HbA1c-only diabetes. Median body mass index, waist and hip circumference, waist-to-hip ratio, subcutaneous adipose tissue and Homoeostatic Model Assessment of Insulin Resistance (HOMA-IR) in participants with HbA1c-only diabetes were similar to those in participants who were normoglycemic by both biomarkers and significantly lower than in participants with diabetes by both biomarkers. HOMA-IR and fat distribution explained additional HbA1c variance beyond glucose and age only in women.
The authors concluded that concordance was poor between HbA1c and FPG in diagnosis of diabetes in black South Africans, and participants with HbA1c-only diabetes phenotypically resembled normoglycemic participants. Further work is necessary to determine which of these parameters better predicts diabetes-related morbidities in this population and whether a population-specific HbA1c threshold is necessary. The study was published on June 17, 2021 in the journal BMJ OPEN.
Related Links:
University of the Witwatersrand
Haemocue
Bio-Rad Laboratories
Randox
Siemens Healthineers
Diagnosis based on glycated hemoglobin (HbA1c) is attractive because it provides an integrated assessment of glycemic status over the preceding three months and has low analytical variability, but the extent to which this single threshold may be adopted in all sub-Saharan African populations is questionable. Existing data suggest that in individuals of African descent, HbA1c may be higher for any given degree of glycaemia than in individuals of European descent.
A large international team of medical scientists led by those at the University of the Witwatersrand (Johannesburg, South Africa) included in a study 765 black individuals aged 40–70 years and with no history of diabetes. The team investigated concordance between hemoglobin A1c (HbA1c)-defined diabetes and fasting plasma glucose (FPG)-defined diabetes in a black South African population with a high prevalence of obesity.
Capillary blood samples were tested for hemoglobin at point of collection using the Haemocue Hb 201+analyser (Haemocue, Ängelholm, Sweden). Whole blood was analyzed for HbA1c using high-performance liquid chromatography on the Bio-Rad D-10 (Bio-Rad Laboratories, Hercules, CA, USA) with a reportable range of 3.8%–18.5%. Plasma was analyzed for glucose using colorimetric methods on the Randox Plus clinical chemistry analyzer (Randox, Crumlin, UK) with a range of 0.36–35 mmol/L. Serum insulin assays were performed on the Immulite 1000 chemistry analysis system (Siemens Healthineers, Erlangen, Germany), using a solid-phase, enzyme-labeled chemiluminescent immunometric assay (range 2–300 μIU/mL).
The investigators reported that the prevalence of HbA1c-defined diabetes was four times the prevalence of FPG-defined diabetes (17.5% versus 4.2%). Classification was discordant in 15.7% of participants, with 111 individuals (14.5%) having HbA1c-only diabetes. Median body mass index, waist and hip circumference, waist-to-hip ratio, subcutaneous adipose tissue and Homoeostatic Model Assessment of Insulin Resistance (HOMA-IR) in participants with HbA1c-only diabetes were similar to those in participants who were normoglycemic by both biomarkers and significantly lower than in participants with diabetes by both biomarkers. HOMA-IR and fat distribution explained additional HbA1c variance beyond glucose and age only in women.
The authors concluded that concordance was poor between HbA1c and FPG in diagnosis of diabetes in black South Africans, and participants with HbA1c-only diabetes phenotypically resembled normoglycemic participants. Further work is necessary to determine which of these parameters better predicts diabetes-related morbidities in this population and whether a population-specific HbA1c threshold is necessary. The study was published on June 17, 2021 in the journal BMJ OPEN.
Related Links:
University of the Witwatersrand
Haemocue
Bio-Rad Laboratories
Randox
Siemens Healthineers
Latest Clinical Chem. News
- Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
- FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
- Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease
- AI Predicts Kidney Stone Composition From Routine Urine Tests
- Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
- Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
- Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease
- New Biomarker Offers Longer Detection Window for Suspected GHB Exposure
- Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction
- Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
- Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
- Combined Blood and Imaging Data Help Identify More Lung Cancer Cases
- Blood Protein Panel Detects ALS with High Accuracy
- Single-Vesicle Analysis Reveals Tissue-Associated Inflammatory Signatures
- Plasma Proteomic Test Detects Immunotherapy Resistance Before Imaging in Lung Cancer
- Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging
Channels
Molecular Diagnostics
view channel
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







